Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 41
- Registration Number
- NCT03713294
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT03657420
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 381
- Registration Number
- NCT03651128
- Locations
- 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸Local Institution - 122, Los Angeles, California, United States
🇺🇸Local Institution - 131, Atlanta, Georgia, United States
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-11-14
- Target Recruit Count
- 18
- Registration Number
- NCT03601624
- Locations
- 🇲🇽
ISSSTE, Ciudad de Mexico, Mexico
Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 26
- Registration Number
- NCT03601806
- Locations
- 🇰🇪
Moi University School of Medicine, Eldoret, Kenya
🇲🇼UNC Project Malawi, Lilongwe, Malawi
🇺🇬Uganda Cancer Institute, Kampala, Uganda
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 46
- Registration Number
- NCT03590652
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT03582033
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center / University of Iowa, Iowa City, Iowa, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT03567616
- Locations
- 🇬🇧
Norfolk and Norwich Univ Hosp /ID# 202240, Norwich, Norfolk, United Kingdom
🇪🇸Hospital Universitario Vall d'Hebron /ID# 200967, Barcelona, Spain
🇺🇸Washington University-School of Medicine /ID# 201287, Saint Louis, Missouri, United States
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 265
- Registration Number
- NCT03539744
- Locations
- 🇺🇸
University of Maryland Medical Center /ID# 217422, Baltimore, Maryland, United States
🇺🇸UPMC Hillman Cancer Ctr /ID# 200063, Pittsburgh, Pennsylvania, United States
🇺🇸Cleveland Clinic Main Campus /ID# 202247, Cleveland, Ohio, United States
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 34
- Registration Number
- NCT03520985
- Locations
- 🇨🇭
Onkozentrum Hirslanden Zürich, Zurich, Switzerland
🇨🇭OnkoZentrum Zürich AG - Klinik im Park, Zürich, Switzerland
🇨🇭Kantonspital Aarau, Aarau, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.